The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure

David Wolinsky, Robert Hendel, Manuel Cerqueira, Michael Gold, Jagat Narula, Jagmeet Singh, Leslee Shaw, Gregory Thomas, Oussama Wazni, Carolyn Farnum

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.

Original languageEnglish (US)
Pages (from-to)S1-S9
JournalAmerican Journal of Cardiology
Volume116
DOIs
StatePublished - Oct 15 2015

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure'. Together they form a unique fingerprint.

  • Cite this

    Wolinsky, D., Hendel, R., Cerqueira, M., Gold, M., Narula, J., Singh, J., Shaw, L., Thomas, G., Wazni, O., & Farnum, C. (2015). The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure. American Journal of Cardiology, 116, S1-S9. https://doi.org/10.1016/j.amjcard.2015.09.014